MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: More good news from Gleevec

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

More good news from Gleevec




Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

Data at this weekends meeting continues to show how much Gleevec has completely changed the outlook for so a number of, a number of patients facing cancer, said Brian Druker, M.D., director of the OHSU Cancer Institute.

At the plenary session of the annual meeting of the American Society of Hematology scientists delivered news that Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).



More good news from Gleevec

Ph+ ALL is the childhood leukemia with the worst prognosis and the Childrens Oncology Group study shows that adding Gleevec to the therapy almost completely reverses this poor prognosis. The Childrens Oncology Group is a worldwide clinical trial cooperative supported by the National Cancer Institute, a branch of the National Institutes of Health.

Also released at the conference is new data from the largest clinical trial in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that showed Gleevec, with long-term use, can prevent progression to advanced stages of the disease.

Six-year results of the International Randomized Interferon versus STI571 (IRIS) study for which Druker served as principal investigator, demonstrated that continuous therapy with Gleevec produced a declining rate of relapse over time.

The downward trend in the risk of disease progression while on Gleevec has continued since year two of the study. Remarkably, between years five and six, no patients progressed to an advanced phase of the disease.

The news about Gleevec and the childhood leukemia study as well as the six-year IRIS study that shows there is no progression to advanced phase in CML means that more and more patients are surviving, despite being diagnosed with these cancers, said Druker, JELD-WEN Chair of Leukemia Research, Howard Hughes Medical Institute Investigator and member of the National Academy of Sciences. He also is a professor of medicine (hematology and medical oncology), cell and developmental biology, and biochemistry and molecular biology in the OHSU School of Medicine.

Gleevec has also been approved for the therapy of gastrointestinal stromal tumors, pediatric CML, as well as five additional rare cancers.


Posted by: Janet    Source




Did you know?
Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia. Data at this weekends meeting continues to show how much Gleevec has completely changed the outlook for so a number of, a number of patients facing cancer, said Brian Druker, M.D., director of the OHSU Cancer Institute.

Medicineworld.org: More good news from Gleevec

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.